News & Updates

Remdesivir may cut the risk of symptoms and diagnoses associated with possible post-COVID conditions (PCC), otherwise known as long COVID.

Individuals with nonalcoholic fatty liver disease (NAFLD) may face stigma from the disease or comorbidities, but the perceptions of shame differ across patients, healthcare providers, geographic locations, and subspecialties, reveals a study.

Phase II data presented at CROI 2024 demonstrated the ability of an investigational, long-acting, oral once-weekly regimen comprising islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor, to maintain viral suppression at week 24 in virologically suppressed people living with HIV (PWH).

Adverse childhood experiences (ACEs) are associated with depression, anxiety, substance use disorder, and stress-related disorders in adulthood, a twin cohort study has shown.